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Lisbon, PortugalBackground: Endoscopic management of postcholecystectomy biliary leaks is widely accepted as the treatment
of choice. However, refractory biliary leaks after a combination of biliary sphincterotomy and the placement of
a large-bore (10F) plastic stent can occur, and the optimal rescue endotherapy for this situation is unclear.
Objective: To compare the clinical effectiveness of the use of a fully covered self-expandable metal
stent (FCSEMS) with the placement of multiple plastic stents (MPS) for the treatment of postcholecystectomy
refractory biliary leaks.
Design: Prospective study.
Setting: Two tertiary-care referral academic centers and one general district hospital.
Patients: Forty consecutive patients with refractory biliary leaks who underwent endoscopic management.
Interventions: Temporary placement of MPS (n Z 20) or FCSEMSs (n Z 20).
Main Outcome Measurements: Clinical outcomes of endotherapy as well as the technical success, adverse
events, need for reinterventions, and prognostic factors for clinical success.
Results: Endotherapy was possible in all patients. After endotherapy, closure of the leak was accomplished in
13 patients (65%) who received MPS and in 20 patients (100%) who received FCSEMSs (P Z .004).
The Kaplan-Meier (log-rank) leak-free survival analysis showed a statistically significant difference between the
2 patient populations (c2 [1] Z 8.30; P! .01) in favor of the FCSEMS group. Use of!3 plastic stents (P Z
.024), a plastic stent diameter!20F (P Z .006), and a high-grade biliary leak (P Z .015) were shown to be sig-
nificant predictors of treatment failure with MPS. The 7 patients in whom placement of MPS failed were retreated
with FCSEMSs, resulting in closure of the leaks in all cases.
Limitations: Non-randomized design.
Conclusion: In our series, the results of the temporary placement of FCSEMSs for postcholecystectomy
refractory biliary leaks were superior to those from the use of MPS. A randomized study is needed to confirm
our results before further recommendations. (Gastrointest Endosc 2015;-:1-9.)ns: FCSEMS, fully covered self-expandable metal stent; MPS,
stic stents.
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Postcholecystectomy refractory biliary leaks Canena et alBiliary leaks can occur after laparoscopic cholecystec-
tomy in 0.3% to 2.7% of patients.1 ERCP has emerged as
a minimally invasive method for the primary treatment
for bile leaks.2-11 The outcome of sealing the leak can be
accomplished by a variety of endoscopic techniques. These
methods include biliary sphincterotomy alone, biliary
stenting with or without sphincterotomy, and nasobiliary
drainage.2-10 All of these methods of endotherapy seem
to be equally effective in allowing the leak to heal in
most cases, but the approach of choice remains controver-
sial.2,8-10 Although there is no consensus regarding the
optimal endoscopic intervention, recent data suggest that
a combination of biliary sphincterotomy and the placement
of a transpapillary biliary stent has a better outcome for
the treatment of high-grade and more complex biliary
leaks.3 However, despite the high success rate and safety
of endotherapy for bile leaks, there are reports of
difficult-to-treat refractory bile leaks that require multiple
endoscopic interventions and sometimes require sur-
gery.3,4,9,10,12 In recent years, the temporary placement of
a fully covered self-expandable metal stent (FCSEMS) has
emerged as an effective rescue therapy for refractory biliary
leaks.12-20 However, in patients with persistent biliary leaks,
instead of using FCSEMSs, the endoscopist could placeO1
plastic stent at a lower cost to further decrease the transpa-
pillary pressure gradient and to seal the leak. However,
costs also should be considered as far as rescue therapy
is concerned. In our country, the cost of an ERCP with
placement of multiple plastic stents (MPS) is U.S. $2200,
and the cost of an ERCP in which a FCSEMS is used is
U.S. $3200. The price of the ERCP is the same for both
treatments, but the placement of an FCSEMS increases
the price by $1000, and this issue can be included in the
treatment decision. Further, in the United States the prob-
lem is similar, being that the price of the ERCP is the same,
but the cost of the stents is different, increasing the price
by O$1000. Until now, there have been no comparative
studies between these 2 types of endoscopic treatment,
and the decisions regarding treatment of a refractory biliary
leak must be made on an individual basis.12,16-18 Therefore,
it is not known whether the MPS used for the closure of a
refractory biliary leak are as successful as the use of an
FCSEMS. We conducted a non-randomized study aiming
to compare the clinical effectiveness of the use of an
FCSEMS with the placement of MPS for the treatment of
postcholecystectomy refractory biliary leaks. Additionally,
we compared the technical success, adverse events, need
for reinterventions, and prognostic factors for clinical
success.METHODS
Patients and setting
This work was a prospective clinical study. Between
May 2010 and September 2013, 2 consecutive cohorts of2 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2015patients with refractory biliary leaks were enrolled in the
study and followed prospectively. The patients were
referred for ERCP if they had a postcholecystectomy biliary
leaks that failed to close after endotherapy, specifically a
combination of biliary sphincterotomy and the placement
of a 10F transpapillary biliary stent. Patients were submit-
ted to endotherapy in 2 consecutive cohorts of 20 patients
each. The first 20 patients were treated with MPS, and the
next cohort of 20 patients was treated with the temporary
placement of FCSEMSs. In each group of consecutive pa-
tients, the treatment was done at the discretion of the en-
doscopist, meaning that the endoscopist was allowed to
choose the number, type, and size of the plastic stents in
the MPS group or the size and type of the metal stent in
the FCSEMS cohort. Further, this decision was done
accordingly with the diameter of the duct and the location
of the leak. Patients with refractory bile leaks with an etiol-
ogy other than postcholecystectomy were excluded from
the study. This study was conducted at 3 institutions (2
tertiary-care referral academic centers and 1 general district
hospital). All of the patients provided informed written
consent before their procedures. Each institutional review
board involved approved this study.
Outcomes and definitions
The primary outcome was the clinical success of each
type of endotherapy, defined as closure of the leak. The
secondary outcomes included the determination of prog-
nostic factors associated with closure of the leak, technical
success, safe removal of the stents, duration of treatment,
adverse events, and the need for reinterventions. Refrac-
tory biliary leaks were defined as leaks that failed to close
after endoscopic intervention with a combination of
biliary sphincterotomy and the placement of a 10F transpa-
pillary biliary stent, regardless of the biliary leak location
(cystic stump, common bile duct and/or common hepatic
duct, Luschka).17 All of the plastic stents used were at
least 7 cm long. High-grade biliary leaks were defined as
leaks observed fluoroscopically before intrahepatic opacifi-
cation.3 Closure of the leak was considered after the
cessation of bile output, which was defined as biliary
drainage of!5 mL/day in the percutaneous drains17 and
confirmed at follow-up ERCP. Failure of endotherapy was
defined as the persistence of biliary drainage through the
percutaneous drain or the persistence of a bile leak at
follow-up ERCP. Reintervention was defined as the need
for further intervention to control the leak after the initial
endotherapy for the refractory leak, including repeat ERCP
for additional stenting or surgery. Adverse events were
defined as any adverse event related to the ERCP or stent
placement, and adverse events were carefully monitored
by using previously determined definitions.13,14,17,21
Intervention, stents, and follow-up
The ERCP procedures were performed with the patient
in the prone position under sedation with propofolwww.giejournal.org
Figure 1. Endoscopic management of a refractory biliary leak by using multiple plastic stents. A, Fluoroscopic image showing persistence of a bile leak
and persistence of biliary drainage through the percutaneous drain after 15 days of plastic stenting. B, Radiograph immediately after endoscopic place-
ment of 3 plastic stents for endotherapy of a refractory bile leak. C, Follow-up cholangiography after plastic stents removal. No contrast media extrava-
sation is seen.
Canena et al Postcholecystectomy refractory biliary leaksadministered by an anesthesiologist. All procedures were
performed by 2 experienced pancreatobiliary endoscopists
(J.C., M.L.). During the study, J.C. performed the endo-
scopic procedures at the 3 participating centers, and M.L.
performed most of the endoscopic examinations in center
1 (Cuf). Patients were considered eligible to enter the
study if, after the first treatment for the biliary leak, the
output of the drain was R600 mL/day at the sixth day,
O500 mL/day after the 10th day, or R400 mL/day at day
15 in association with maintenance or worsening of the
bilious fluid collections on abdominal US or on a CT
scan. During the initial ERCP procedure, a diagnostic chol-
angiogram was obtained for documenting the site and
grade of the refractory biliary leak. For treatment with
MPS, the endoscopist determined the number and diam-
eter of the stents to be inserted on the basis of the diam-
eter of the bile duct (Fig. 1). Although this decision was
left to the discretion of the endoscopist, there was
always an effort to place the maximum number of stents
allowed by the size of the duct. Smaller ducts were
treated with a combination of a lower number of stents
(eg, a small duct with a diameter of 5 mm was treatedwww.giejournal.orgwith 2 stentsd1 of 10F þ 1 of 8.5F; a large duct with a
diameter of 10 mm was treated with R3 stents of 10F).
For this treatment, polyethylene stents were used in all
cases (Advanix biliary stent; Boston Scientific, Natick,
Mass. Cotton-Huibregtse biliary stent; Cook Medical,
Winston-Salem, NC). For FCSEMS treatment, the guide-
lines of the study included the following: (1) Patients in
whom the bile duct had a diameter of %5.0 mm were
treated with FCSEMSs having an 8-mm luminal diameter
and a length that varied from 40 to 80 mm to allow the
stent to be placed above the leak site in all cases. (2) Pa-
tients in whom the bile duct diameter was O5.0 mm
were treated with FCSEMSs having 10-mm luminal diame-
ters (Video 1, available online at www.giejournal.org). In
the FCSEMS approach, 2 types of stents were used:
WallFlex (Boston Scientific) and the Niti-S (TaeWoong
Medical, Seoul, South Korea). All of the patients were
treated and monitored with a percutaneous drain, and
the drainage output was used to evaluate the success of
stent placement in closing the bile leak. The placement
of a percutaneous drain was an inclusion criterion for
the study. The drains were placed at 2 different times:Volume -, No. - : 2015 GASTROINTESTINAL ENDOSCOPY 3
TABLE 1. Demographics and baseline characteristics of patients
Characteristic Metal stents Plastic stents P value
Sex, no. (%) .204
Male 9 (45) 13 (65)
Female 11 (55) 7 (35)
Age, median (range, mean), y 62 (32-89, 59.8) 61.5 (23-84, 59.8) .914
Site of bile leak, no. (%) .490
Cystic duct stump 15 (75) 13 (65)
Common bile duct/common hepatic duct 5 (25) 7 (35)
Type of leak, no. (%) .507
High grade 14 (70) 12 (60)
Low grade 6 (30) 8 (40)
Time interval until first rescue ERCP,
median (range, mean), d
10 (7-24, 10.6) 10.5 (6-16, 11.1) .390
Output of the percutaneous drain 1 d before patient entered the study,
median (range, mean), mL/d
620 (780-590, 644.2) 650 (800-450, 666.1) .630
Postcholecystectomy refractory biliary leaks Canena et alduring surgery when injury was suspected or before the
first ERCP when a bilious fluid collection was found.
The drains stayed in place during the study until cholangio-
graphic documentation of clinical success of the rescue
therapy was obtained. After clinical evidence of complete
resolution of the initial condition, the patients were sched-
uled for a second ERCP in which the stents were
removed by using rat-toothed forceps or a cold snare at
the discretion of the endoscopist (Video 2, available
online at www.giejournal.org). During the second ERCP,
a new cholangiogram was obtained for documenting the
closure of the leak. However, after the first treatment for
the refractory biliary leak, patients with drain outputs
O300 mL/day after the 10th day in association with
maintenance or worsening of the bilious fluid collections
on abdominal US or on a CT scan were considered to
be treatment failures and were subjected to a second
ERCP. After confirmation of a persistent bile leak,
patients previously subjected to treatment with MPS were
retreated with FCSEMSs, and the patients initially treated
with FCSEMSs were considered for surgery.
For all patients, the follow-up continued for at least 6
months after the end of treatment and closure of the
leak. The patients were followed-up with blood analyses
and upper abdominal US at 3 and 6 months after discharge
from the hospital.
Statistical analysis
The intention-to-treat method was used in all of the an-
alyses. The c2 test, the Mann-Whitney U test, and the
Fisher exact test were used to calculate the statistical signif-
icance of different demographic and clinical variables when
appropriate. The cumulative leak-free survival (clinical suc-
cess) was evaluated by using the Kaplan-Meier method,
and the groups were compared by using the log-rank4 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2015test. The 95% confidence interval (CI) for long-term,
leak-free survival was calculated with the Clopper-Pearson
(exact) method. The potential prognostic factors associ-
ated with closure of the leaks were assessed by using a uni-
variate analysis that was conducted by using the Fisher
exact test for categorical variables and the Mann-Whitney
U test for continuous variables. All of the reported P values
were for a 2-tailed test, and P! .05 was considered statis-
tically significant. All of the statistical analyses were per-
formed by using the software package SPSS, version 22
(Statistical Package for the Social Sciences, IBM Corpora-
tion, Armonk, NY).RESULTS
Between May 2010 and September 2013, 40 patients
(22 male and 18 female) with a median age of 62 years
(range 23-89 years) were enrolled in the study. Twenty pa-
tients were included in each group. All of the patients
had a refractory biliary leak located at the cystic stump or
at the common bile duct and/or common hepatic duct.
The patient demographics, bile leak location, type of leak
characteristics, output of the percutaneous drain before
the study was begun, and interval between the first ERCP
and second endoscopic intervention for the refractory
biliary leak are summarized in Table 1. There were no
significant differences in the demographics and baseline
characteristics of the 2 groups defined in the Methods
section. The 40 patients included were treated as follows:
In center 2 (Pulido Valente) J.C. performed 19 cases (9 in
the MPS group and 10 in the FCSEMS group). In center
3 (Beja) J.C. performed 11 cases (7 in the MPS group
and 4 in the FCSEMS group). In center 1 (Cuf) M.L.
performed 9 cases (4 in the MPS group and 5 in thewww.giejournal.org
TABLE 2. Comparative outcomes between plastic stents and metal stents after endoscopic management of refractory biliary leaks, including
adverse events
Outcome Plastic stents Metal stents
Clinical success of rescue endotherapy, no. (%) 13/20 (65) 20/20 (100)*
Cessation of bile output in percutaneous drains, time, median (range), d 11 (8-17) 3.5 (2-9)
Duration of stenting, time, median (range), d 56 (26-82) 17 (8-29)
Adverse events, stent-related, no. (%) 0 (0) 2 (10), mild pancreatitis
*c2 Z 8.485; P Z .004.
Canena et al Postcholecystectomy refractory biliary leaksFCSEMS group), and J.C. performed 1 case (FCSEMS
group).
First endoscopic treatment for refractory
biliary leaks
Stent implantation was technically successful in all pa-
tients. The endoscopic management of refractory biliary
leaks is shown in Table 2. Regarding the clinical success
of the first rescue endotherapy, 33 of 40 patients (82.5%)
who received temporary placement of MPS or FCSEMSs
had their bile leaks closed. In the group of patients
subjected to the temporary placement of MPS, 13 of 20
patients (65%) experienced closure of the biliary leak. In
the 13 patients with clinical success, ceased bile output
in the percutaneous drains was seen after a median time
of 11 days (range 8-17 days), and the plastic stents were
removed after a median period of 56 days (range 22-82
days). In this group of 13 successfully treated patients,
the median value of the maximum number of stents
simultaneously inserted was 3 (range 2-5), and the
median maximum stent diameter was 25.5F (range 20F-
35.5F). In the remaining 7 patients without clinical
success, the median value for the maximum number of
stents simultaneously inserted was 2 (range 2-2), and the
median maximum stent diameter was 20F (range 18.5F-
20F). The range of French gauge for MPS placement was
calculated from the sum of the French gauges of the
stents implanted at the same procedure (eg, 2  10F and
1  8.5F would be 2  10 Z 20 þ 1  8.5 Z 8.5, which
would be 28.5) as suggested elsewhere.11 Clinical success
was achieved in all of the 20 patients treated with
FCSEMSs. In this group, cessation of bile output in the
percutaneous drains was observed after a median time of
3.5 days (range 2-9 days), and the metal stents were
removed after a median period of 17 days (range 8-29
days). In the 20 patients submitted to the temporary
placement of an FCSEMS, 8 patients were treated with
the Niti-S stent and 12 with the WallFlex stent. There
were no differences in clinical success, median time of
stenting, adverse events (namely pancreatitis), and safe
removal of the stents among the 2 groups of patients.
Regarding the clinical success, there was a significant differ-
ence between the 2 types of endotherapy in favor of
the use of the FCSEMS (c2 Z 8.485; P Z .004).www.giejournal.orgFollow-up, reinterventions, and adverse events
The remaining 7 patients in whom the placement of
MPS was unsuccessful were considered clinical failures
because of similar or increased levels of percutaneous
drainage and maintenance of the bilious fluid collections
on abdominal US or on a CT scan. In this group of 7 pa-
tients, the output of the percutaneous drain 1 day before
the placement of the FCSEMS was as follows: median
395 mL/day (range 345-520 mL/day). The follow-up ERCP
with the removal of the plastic stents confirmed the persis-
tence of a biliary leak. All 7 of the patients were treated
again with the placement of an FCSEMS. At the end of
this new endoscopic management, clinical success was
obtained in all of the patients. In this group of 7 patients
treated again with an FCSEMS, cessation of bile output in
the percutaneous drains was observed after a median
time of 5 days (range 4-10 days), and the metal stents
were removed after a median period of 28 days (range
14-30 days). Further, in this group of 7 patients, 3 were
treated again with the Niti-S, and 4 were treated again
with the WallFlex stent. There were no differences in clin-
ical success, median time of stenting, adverse events, and
safe removal of the stents among the 2 groups of patients.
Overall, in the 27 patients treated with an FCSEMS, the
stent removal attempts were achieved without difficulty.
In this group of 27 patients, the mid bile duct diameter
was initially measured, with values ranging from 5.3 mm
to 13.2 mm. After FCSEMS placement, the bile duct
assumed the shape and diameter of the stent (for bile
ducts !10 mm), returning to normal after FCSEMS
removal. At the end of the study, none of the patients
was referred for surgery, and endotherapy proved to be
successful in all cases.
In the MPS group, there were no adverse events related
to the ERCP or stents. In the group of patients treated
with an FCSEMS, no adverse events related to the ERCP
were observed. However, in 2 of 20 patients (10%) sub-
jected to FCSEMS placement, mild pancreatitis was
observed, and this adverse event was considered to be
stent related. In these 2 cases, the patients were managed
conservatively. There were no cases of metal stent migra-
tion, duodenal ulcerations, or de novo choledocholithiasis
and bile duct strictures found within the FCSEMSs or bile
ducts at the time of stent removal.Volume -, No. - : 2015 GASTROINTESTINAL ENDOSCOPY 5
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Figure 2. Kaplan-Meier analysis of leak-free survival rates (clinical
success) after first rescue endoscopic treatment with multiple plastic
stents for a refractory biliary leak (solid line) and 95% confidence
interval (dashed line).
Postcholecystectomy refractory biliary leaks Canena et alLeak-free survival and univariate analysis of
prognostic factors associated with closure of
the leak
After endoscopic treatment with MPS, the Kaplan-Meier
analysis showed that the estimated cumulative mean time
of clinical success was 23.1 days (95% CI, 18.9-27.3 days).
By the end of endotherapy with MPS, the leak-free survival
rate was 65% (95% CI, 44.0%-86.0%) at 30 and 60 days
(Fig. 2). The comparison of leak-free survival between
the patients treated with MPS and the patients subjected
to FCSEMS placement by using a log-rank test showed
a statistically significant difference between the 2 patient
populations (c2 [1] Z 8.30; P! .01), and this result was
in favor of the patients who underwent FCSEMS stenting.
The univariate analysis of treatment failure with MPS
is shown in Table 3. Of the 7 evaluated variables (sex,
age, maximum number of stents inserted, maximum
stent diameter, biliary leak location, type of leak, and
interval between first endoscopic treatment and second
ERCP for refractory bile leak), the use of !3 plastic
stents, a low plastic stent diameter (!20F), and a high-
grade biliary leak proved to be statistically significant pre-
dictors of treatment failure of a refractory biliary leak
with MPS (P! .01).DISCUSSION
According to our findings in this prospective, non-
randomized study of 2 consecutive cohorts of patients
with refractory biliary leaks after the combination of biliary
sphincterotomy and the placement of large-bore (10F)
plastic stents, the temporary placement of an FCSEMS is
the treatment of choice. The use of MPS seems to be
less preferable, leading to fewer cases (65%) of clinical suc-
cess. Additionally, the use of!3 plastic stents, a plastic6 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2015stent diameter!20F, and a high-grade biliary leak were
associated with treatment failure by using MPS.
With the era of laparoscopic approaches, the number of
biliary leaks after cholecystectomy has increased, creating
the necessity for minimally invasive procedures to manage
these leaks and potentially reduce morbidity and mortal-
ity.1,9,10 ERCP has emerged as the primary treatment; the
goal of ERCP is to reduce the pressure gradient between
the bile duct and duodenum, therefore creating a preferen-
tial flow of bile into the duodenum and allowing the
defect to heal.1,2,8 A variety of ERCP techniques have
been used, including biliary stenting, nasobiliary drainage,
biliary sphincterotomy, or a combination of these proce-
dures.2-10 All of these techniques have proven to be effec-
tive in most cases, and the approach of choice remains
controversial because each type of endotherapy has merits
and limitations.2,9,10 For simple leaks such as small cystic
duct leaks (low-grade leaks) and Luschka duct leaks,
the success rate of endotherapy is high. However, in a small
subset of patients with more complex leaks (high-grade
cystic stump leaks, common bile duct and/or common he-
patic duct leaks, bile leaks after liver transplantation, or
large leaks after partial cholecystectomy), successful closure
can be more problematic.3,4,12,16,17 In a retrospective study
of 207 patients who had high-grade leaks, Sandha et al3
reported that these leaks could be managed better with a
combination of biliary sphincterotomy and stenting,
suggesting that this modality has the highest potential for
sealing a biliary leak. In the current study, we chose a
standard and homogeneous approach to try to maximize
the benefits of the first endoscopic treatment. Therefore,
all patients with a leak were initially treated with a
combination of biliary sphincterotomy and placement of a
large-bore (10F) plastic stent.
However, even after the combination of stenting and
sphincterotomy, refractory biliary leaks can occur, and
recently, the temporary placement of an FCSEMS has
been shown to be an efficacious rescue therapy, with suc-
cess rates ranging from 90.5% to 100%14-20 (Table 4). The
large stent diameter diverts more flow away from the
leak site, causing a significant decrease in the pressure
gradient at the papilla. Furthermore, in biliary ducts
where the diameter at the site of the leak is!10 mm,
the FCSEMS directly covers the leak site, increasing the
potential for sealing the leak. This would be true only of
cystic duct and common bile duct and/or common
hepatic duct leaks. Refractory bile leaks above the
bifurcation are usually poor candidates for FCSEMS
placement as the placement of the metal stent across the
bifurcation as the potential of obstructing drainage from
the other side of the liver. Baron and Poterucha12 first
reported the use of partially covered (n Z 2) and fully
covered (nZ 1) self-expandable metal stents in 3 patients
with complex biliary leaks of the gallbladder bed after open
subtotal cholecystectomy procedures. That study reported
a 100% rate of clinical success. Wang et al14 reportedwww.giejournal.org
TABLE 4. Studies reporting the use of fully covered self-expandable metal stents for endoscopic management of benign biliary disease including
bile leaks
First
author
Patients,
no.
Biliary
leaks, no. Etiology
Closure of
leaks, no. (%)
Duration of stenting,
median (range), d
Adverse events, no. (%),
type of adverse event (no.)
Wang14 13 13 Chole and OLT 13/13 (100) 103 (67-493) 3/13 (23)
Bile duct strictures (2)
ampullary adenoma (1)
Canena17 25 17 Chole 17/17 (100) 16 (7-28) 0
Akbar18 37 21* Chole 19/21 (90.5) NA NA
Lalezari19 17 5 Chole 5/5 (100) 92 (48-251) 2/5 (40)
Hepatic abscess and sepsis (1)
occluded stent (1)
Phillips22 17 17 OLT 16/17 (94.1) 102 (35-427) 6/17 (35)
Bile duct strictures (6)
Chole, Postcholecystectomy; OLT, orthotopic liver transplantation; NA, not available related with the bile leak group.
*Some patients had a partially covered self-expandable metal stent.
TABLE 3. Univariate analysis of prognostic factors associated with closure of leaks in patients treated with placement ofR2 biliary plastic stents
(MPS)
Factor
Closure of leak
P valueNo Yes
Sex, no. (%) .658
Male 5 (38.5) 8 (61.5)
Female 2 (28.6) 5 (71.4)
Age, median (range, mean), y 64 (23-84, 59.0) 64 (39-79, 61.1) .874
Site of bile leak, no. (%) .174
Cystic duct stump 3 (23.1) 10 (76.9)
Other than cystic duct stump 4 (57.1) 3 (42.9)
Maximum no. plastic stents inserted, median (range, mean) 2 (2-2, 2.0) 3 (2-5, 2.9) .024*
Maximum plastic stent diameter reached, median (range, mean), F 20 (18.5-20, 19.6) 25.5 (20-35.5, 25.4) .006*
Time interval until first rescue ERCP, median (range, mean), d 8 (6-15, 9.6) 13 (7-16, 11.9) .130
Type of leak, no. (%) .015*
High grade 7 (58.3) 5 (41.7)
Low grade 0 (0) 8 (100)
*P! .05.
Canena et al Postcholecystectomy refractory biliary leaksthe first case series with the use of FCSEMSs to treat a
heterogeneous group of 13 patients with complex leaks.
Although the bile leaks resolved in all patients, several
adverse events were reported, and the prolonged
FCSEMS placement was associated with the majority of
the adverse events. However, a recent study evaluated
17 patients with refractory biliary leaks. All patients were
successfully treated with an FCSEMS placed for %30
days without adverse events, suggesting that short-term
stenting is efficacious and is not associated with adverse
events.17 However, some authors speculate that a
refractory biliary leak could eventually be managed by
upsizing the existing plastic stent or adding additional
plastic stents, avoiding the costs of an FCSEMS.12,16-18 In
this study, we compared the placement of an FCSEMS
with MPS, and we found significant differences. FCSEMSwww.giejournal.orgplacement sealed the leak in 100% of patients compared
with a clinical success rate of 65% in the patients subjected
to MPS placement. Furthermore, in the 13 cases of success
by using the MPS treatment, cessation of bile output in the
percutaneous drains was observed after a median time of
11 days, which compares poorly with the results of the
FCSEMS group, in which cessation of bile output in the
percutaneous drains was observed after a median time of
3.5 days. These results suggest that even in cases of suc-
cess, the MPS strategy is associated with a longer time to
seal the leak and prolonged hospital stays compared with
the temporary placement of an FCSEMS. More reinterven-
tions were required in the MPS group because 7 of the pa-
tients did not achieve clinical success. These patients were
retreated with an FCSEMS, which proved to be successful
even in the cases refractory to the initial rescue therapyVolume -, No. - : 2015 GASTROINTESTINAL ENDOSCOPY 7
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were superior to those of MPS in terms of several variables,
including the clinical success rate, duration of treatment,
and need for reinterventions.
The use of!3 plastic stents, a plastic stent diameter
!20F, and a high-grade biliary leak were significant pre-
dictors of treatment failure with MPS. These observations
suggest, with caution, the following: (1) All patients with
refractory high-grade bile leaks should be treated with
FCSEMSs, and (2) if treatment of a refractory bile leak
by using MPS is considered, at least 3 stents with a diam-
eter O20F should be used. In our series, all patients with
low-grade refractory biliary leaks were successfully treated
with MPS. We could eventually suggest that patients with
refractory, low-grade, biliary leaks could be treated with
MPS, reducing costs and decreasing the incidence of
pancreatitis. However, as previously mentioned, a suc-
cessful outcome by using MPS is associated with a longer
treatment time compared with the placement of an
FCSEMS, and this should be evaluated carefully in terms
of costs and quality of life in future studies before this
recommendation is made.
The temporary placement of an FCSEMS is safe. Several
adverse events have been described in small series with
long-term duration of stent placement14,18,19,22 (Table 4),
but these adverse events can be avoided by short-term
stenting. Further, in most of the studies concerning
benign biliary diseases, including strictures, the migration
rate wasO30%. In a recent study of 17 patients with post-
cholecystectomy refractory biliary leaks, short-term stent-
ing (!30 days) was clinically efficacious and was
associated with the absence of early and late adverse
events, including migration, after a median follow-up of
125 weeks.17 In this study, short-term stenting was associ-
ated with a low adverse event rate, and we believe that
the shorter the duration of stenting the lower the probabil-
ity of migration. Special concerns have been raised con-
cerning de novo biliary strictures after temporary FCSEMS
placement (especially after long-term stenting),14 in liver
transplant patients22 and after oversizing (placement of a
10-mm stent in a duct with a smaller diameter).23 At the
end of the study, the oversizing in bile ducts with luminal
diameters O5.0 mm was safe, and none of our 27
patients who had FCSEMSs placed developed de novo
stricture formation. This was related to the short-term
stenting as suggested in the previously mentioned report.17
Finally, in our study, as suggested elsewhere,23 the removal
of an FCSEMS was safe and easily accomplished.
The present study has several limitations. First, our non-
randomized design could have introduced sampling bias.
However, there were no major differences in the demo-
graphics, bile leak location, type of leak characteristics,
and interval between first ERCP and the second endo-
scopic intervention between the 2 groups studied. We sug-
gest that a prospective multicenter randomized study
should be performed to confirm our results in a larger8 GASTROINTESTINAL ENDOSCOPY Volume -, No. - : 2015population and to allow a multivariate analysis, which
would give much stronger conclusions. In this proposed
future study, the length of the hospital stay and the costs
should be carefully evaluated. Another potential weakness
of our study is the fact that this study was performed only
by very experienced endoscopists, and we cannot exclude
the possibility of obtaining a poorer outcome in commu-
nity hospitals. Strengths of our study include the prospec-
tive design, the relatively large sample size (refractory bile
leaks are uncommon), and the newly reported findings. To
our knowledge, this is the first study to compare the 2
types of rescue endoscopic management techniques avail-
able for the treatment of postcholecystectomy refractory
biliary leaks.
In conclusion, in our series and in our centers the results
of using an FCSEMS as rescue endotherapy for postchole-
cystectomy refractory biliary leaks were superior to those
with the use of MPS. We suggest that a randomized clinical
trial is needed before the temporary placement of an
FCSEMS is recommended as the treatment of choice.REFERENCES
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